<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR4">
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Barnes</surname>
    <given-names>GL</given-names>
   </name>
   <name>
    <surname>Lund</surname>
    <given-names>JS</given-names>
   </name>
   <name>
    <surname>Mitchell</surname>
    <given-names>SV</given-names>
   </name>
   <name>
    <surname>De Bruyn</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Piggford</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>AL</given-names>
   </name>
   <name>
    <surname>Furmedge</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Masendycz</surname>
    <given-names>PJ</given-names>
   </name>
   <name>
    <surname>Bugg</surname>
    <given-names>HC</given-names>
   </name>
   <name>
    <surname>Bogdanovic-Sakran</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Carlin</surname>
    <given-names>JB</given-names>
   </name>
   <name>
    <surname>Bishop</surname>
    <given-names>RF</given-names>
   </name>
  </person-group>
  <article-title>Early phase II trial of human rotavirus vaccine candidate RV3</article-title>
  <source>Vaccine</source>
  <year>2002</year>
  <volume>20</volume>
  <fpage>2950</fpage>
  <lpage>2956</lpage>
  <pub-id pub-id-type="doi">10.1016/S0264-410X(02)00235-9</pub-id>
  <pub-id pub-id-type="pmid">12126907</pub-id>
 </element-citation>
</ref>
